~~<i id='A4B5186725'><strike id='A4B5186725'><tt id='A4B5186725'><pre id='A4B5186725'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：Wikipedia 2025-10-02 02:16:09 - browse：34537

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Australia’s approach to dialysis celebrates life

hotspot

focus

knowledge

entertainment

VincentMajor(left)andCristinaGonzalezattheprompt-a-thonorganizedbyNYULangone.CourtesyJoeCarrotta/NYU

WSS

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Winners, losers from Medicare’s list of drugs subject to price talks

Snowpack in the West is melting rapidly. Where will all that extra water go?

HCA says smaller share of spending going to labor

Diversity in medical illustrations gets boost from Chidiebere Ibe

How to make AI work for medicine

hotspot

Wikipedia

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Duchenne breakthrough therapy leaves behind pioneering families

As pharma fights Medicare drug negotiation, hospitals, docs silent

Cancer drug shortages should be causing more outrage

As pharma fights Medicare drug negotiation, hospitals, docs silent

As demand for Covid shots wanes, Moderna seeks its next success

Radiation, mainstay of cancer treatment, begins a fade

Novavax promises a turnaround & Lilly roils the obesity market

Many immigrants are left out of maternal health programs

hotspot

CDC advisory panel says seniors 'may' get RSV vaccine

AstraZeneca challenges Medicare drug negotiation program

How to make Best Hospitals ratings actually useful for patients

Campaign finance charge dropped from case against Sam Bankman

Feds fine Medicare Advantage plans for overcharging members

Medicare explains how it will choose drugs for negotiation

focus

focus

knowledge

entertainment